TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. (2021)
Attributed to:
Overcoming Ibrutinib and Venetoclax resistance in Chronic Lymphocytic Leukaemia.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.2020005964
PubMed Identifier: 33512408
Publication URI: http://europepmc.org/abstract/MED/33512408
Type: Journal Article/Review
Volume: 137
Parent Publication: Blood
Issue: 22
ISSN: 0006-4971